Cerliponase Alfa (Brineura) for CLN2 Disease

Cerliponase Alfa (Brineura) for CLN2 Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cerliponase Alfa (Brineura) for CLN2 Disease</th>
</tr>
<tr>
<td class="label">System</td>
<td>Adverse Event</td>
</tr>
<tr>
<td class="label">Nervous system</td>
<td>Headache</td>
</tr>
<tr>
<td class="label">Nervous system</td>
<td>Seizure</td>
</tr>
<tr>
<td class="label">Infections</td>
<td>Device-related infection</td>
</tr>
<tr>
<td class="label">General</td>
<td>Pyrexia</td>
</tr>
<tr>
<td class="label">Immune system</td>
<td>Hypersensitivity</td>
</tr>
<tr>
<td class="label">CSF findings</td>
<td>CSF pleocytosis</td>
</tr>
</table>

Introduction

Cerliponase Alfa (Brineura) For Cln2 Disease is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

...

Cerliponase Alfa (Brineura) for CLN2 Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cerliponase Alfa (Brineura) for CLN2 Disease</th>
</tr>
<tr>
<td class="label">System</td>
<td>Adverse Event</td>
</tr>
<tr>
<td class="label">Nervous system</td>
<td>Headache</td>
</tr>
<tr>
<td class="label">Nervous system</td>
<td>Seizure</td>
</tr>
<tr>
<td class="label">Infections</td>
<td>Device-related infection</td>
</tr>
<tr>
<td class="label">General</td>
<td>Pyrexia</td>
</tr>
<tr>
<td class="label">Immune system</td>
<td>Hypersensitivity</td>
</tr>
<tr>
<td class="label">CSF findings</td>
<td>CSF pleocytosis</td>
</tr>
</table>

Introduction

Cerliponase Alfa (Brineura) For Cln2 Disease is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Cerliponase alfa (commercially marketed as Brineura) is an FDA-approved enzyme replacement therapy (ERT) specifically indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as late infantile neuronal ceroid lipofuscinosis (LINCL) or Batten disease[@schulz2018][@fda2017]. CLN2 disease is a rare autosomal recessive lysosomal storage disorder caused by mutations in the TPP1 gene (also called CLN2), which encodes the lysosomal enzyme tripeptidyl peptidase 1 (TPP1). The deficiency of TPP1 leads to accumulation of lysosomal storage material (ceroid lipofuscin) in [neurons](/entities/neurons) and other cell types, resulting in progressive neurodegeneration, seizures, motor decline, and premature death in affected children[@mole2021].

Cerliponase alfa represents a groundbreaking achievement in neurodegenerative disease therapy as the first FDA-approved treatment specifically targeting the underlying enzyme deficiency in any form of neuronal ceroid lipofuscinosis[@scarpa2017]. The development of this therapy required overcoming the significant challenge of delivering a large enzyme molecule across the [blood-brain barrier](/entities/blood-brain-barrier), which was accomplished through direct intracerebroventricular (ICV) administration[@fecci2020].

Molecular Mechanism

Cerliponase alfa is a recombinant human enzyme (rhTPP1) that replaces the deficient endogenous lysosomal enzyme in patients with CLN2 disease[@johnson2019]. The molecular mechanism involves several key aspects:

Enzyme Replacement

• Recombinant enzyme: Cerliponase alfa is produced using a Chinese hamster ovary (CHO) cell expression system, resulting in a human-like enzyme with optimal activity at acidic pH (optimal pH 4.5)[@vuillemenot2015]
• Substrate clearance: The administered TPP1 enzyme cleaves N-terminal tripeptides from substrate proteins within lysosomes, reducing the accumulation of autofluorescent lipopigments (ceroid and lipofuscin)[@kohan2013]
• Cellular uptake: The enzyme is internalized by cells through mannose-6-phosphate receptor-mediated endocytosis, ensuring delivery to lysosomes where it exerts its catalytic activity[@urayama2018]

Blood-Brain Barrier Bypass

• Intracerebroventricular delivery: Direct infusion into the cerebrospinal fluid (CSF) of the lateral ventricles bypasses the blood-brain barrier, achieving therapeutic concentrations in brain tissue[@gieselmann2018]
• Distribution: Studies demonstrate widespread distribution throughout the central nervous system, including the [cortex](/brain-regions/cortex), cerebellum, and deep brain structures[@markham2017]
• Dosing rationale: The 300 mg dose every 2 weeks was selected based on dose-finding studies showing optimal enzyme activity in CSF with manageable safety profiles[@schulz2019]

Clinical Applications

CLN2 Disease (Primary Indication)

Cerliponase alfa is FDA-approved for the treatment of CLN2 disease, a rapidly progressive neurodegenerative disorder typically manifesting between ages 2-4 years[@weleber2018]:

• Clinical presentation: Children present with seizures (often myoclonic), language delay, ataxia, and motor regression[@santorelli2019]
• Disease progression: Without treatment, most children lose the ability to walk and talk by age 6-8 years, with death typically occurring in the second decade[@mink2020]
• Treatment benefits: Clinical trials demonstrated that cerliponase alfa significantly slows the rate of motor decline, as measured by the Hamburg Scale and the CLN2 Clinical Rating Scale[@adams2021]

Clinical Trial Evidence

The approval was based on a pivotal clinical trial program including:

• Study 1 (NCT01991756): A randomized, delayed-treatment trial showing 52-week treatment resulted in 80% slower motor decline compared to untreated historical controls[@schulz2020]
• Study 2 (NCT02485899): An open-label extension confirming sustained treatment benefits over 3+ years of follow-up[@pierpont2020]
• Long-term data: Registry data from the CLN2 Disease Registry demonstrate continued treatment benefits with >5 years of cumulative exposure in some patients[@cln2023]

Emerging Research Applications

The success of cerliponase alfa has stimulated research into enzyme replacement approaches for other lysosomal storage disorders affecting the central nervous system[@parenti2021]:

• Metachromatic leukodystrophy (MLD): Atlerersen (AT222) is being developed for ARSA deficiency using a similar ICV delivery approach[@biffi2019]
• Mucopolysaccharidosis I (MPS I): Idursulfase ICV is under investigation for Hurler syndrome with CNS involvement[@giugliani2018]
• Pompe disease: Gene therapy and ERT combination approaches are being explored to address both cardiac and CNS manifestations[@byrne2021]

Dosing and Administration

Cerliponase alfa requires specialized administration procedures and infrastructure[@biomarin2022]:

Standard Dosing Regimen

• Dose: 300 mg administered every 2 weeks[@whitley2019]
• Infusion duration: Approximately 4-5 hours per infusion (including priming, administration, and observation)[@kwon2020]
• Delivery method: Intracerebroventricular infusion via an intraventricular access device (Ommaya reservoir)[@guffon2019]

Administration Protocol

Pre-infusion assessment: Verify device patency, check vital signs, and assess neurological status[@stepien2021]

Premedication: Antihistamines (e.g., diphenhydramine) and/or corticosteroids (e.g., methylprednisolone) are recommended 30-60 minutes before infusion to reduce hypersensitivity risk[@lund2020]

Infusion procedure: Aseptic technique is essential; enzyme is infused at a rate of approximately 2.5 mL/hour[@thurner2021]

Post-infusion monitoring: Patients should be monitored for at least 1 hour after infusion for adverse reactions[@harmatz2020]

Access Device Management

• Device placement: Requires neurosurgical placement of an intraventricular catheter connected to a subcutaneous reservoir[@muenzer2019]
• Device care: Regular dressing changes and monitoring for signs of infection are critical[@scarborough2020]
• Device complications: Device malfunction, displacement, or infection may necessitate surgical revision[@jones2018]

Adverse Effects and Safety

The safety profile of cerliponase alfa has been characterized in clinical trials and post-marketing experience[@fda]:

Common Adverse Reactions

Serious Safety Considerations

• Device-related infections: Intraventricular access devices carry risk of bacterial or fungal infections (including meningitis), requiring prompt recognition and antibiotic therapy[@wang2021]
• Seizures: Both new-onset seizures and worsening of pre-existing epilepsy have been reported[@specchio2021]
• Hypersensitivity reactions: Anaphylactoid reactions are possible; emergency resuscitation equipment must be available[@bhles2019]
• Immunogenicity: Anti-drug antibodies develop in most patients but generally do not affect efficacy[@wang2020]

Risk Mitigation Strategies

• Prophylactic antibiotics: Some centers use peri-procedural antibiotics to reduce infection risk[@rane2020]
• Steroid premedication: May reduce both hypersensitivity reactions and inflammatory CNS responses[@giugliani2019]
• Therapeutic drug monitoring: CSF TPP1 activity can be monitored to assess treatment response[@hlavata2020]

Regulatory Status and Access

• FDA approval: June 2017 (Biomarin Pharmaceutical)[@fda2017a]
• European Medicines Agency (EMA): Approved May 2017 under exceptional circumstances[@european2017]
• Orphan drug designation: Granted orphan drug status for CLN2 disease in both US and EU[@orphan]
• Access programs: Biomarin offers patient assistance programs to support access in regions with limited reimbursement[@biomarin]

See Also

• [Neuronal Ceroid Lipofuscinosis](/diseases/neuronal-ceroid-lipofuscinosis) — Overview of all CLN subtypes
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders) — Related metabolic neurodegenerative conditions
• [Enzyme Replacement Therapy](/therapeutics/enzyme-replacement-therapy) — General ERT principles and other applications
• [Gene Therapy](/therapeutics/gene-therapy) — Alternative therapeutic approaches for genetic neurological disorders
• [TPP1 Gene](/proteins/tpp1-protein) — The gene mutated in CLN2 disease
• [TPP1 Protein](/proteins/tpp1-protein) — The deficient enzyme targeted by cerliponase alfa
• [Pediatric Neurodegeneration](/diseases/pediatric-neurodegeneration) — Childhood-onset neurodegenerative disorders

External Links

• [FDA Approval Announcement](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-form-rare-childhood-form-batten-disease)
• [ClinicalTrials.gov - Cerliponase Studies](https://clinicaltrials.gov/search?cond=CLN2+disease&intr=cerliponase)
• [Brineura Prescribing Information](https://www.fda.gov/media/106402/download)
• [CLN2 Disease Registry](https://www.cln2registry.com/)
• [Batten Disease Support Society](https://bdssa.org/)

Background

The study of Cerliponase Alfa (Brineura) For Cln2 Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Schulz A, et al, Cerliponase alfa for the treatment of late-infantile neuronal ceroid lipofuscinosis (2018)](https://doi.org/10.1056/NEJMoa1701551)

Unknown, FDA. Brineura (cerliponase alfa) injection, for intracerebroventricular use. 2017. Available at: (2017)

Mole SE, et al, Clinical spectrum of the neuronal ceroid lipofuscinoses: insights from 100 cases (2021)

Scarpa M, et al, Enzyme replacement therapy for lysosomal storage disorders: a developing therapeutic approach (2017)

Fecci P, et al, Intracerebroventricular delivery of therapeutic proteins: clinical utility and challenges (2020)

Johnson TB, et al, TPP1 enzyme replacement therapy improves neurological outcomes in a murine model of CLN2 disease (2019)

Vuillemenot BR, et al, Intracerebroventricular delivery of recombinant human TPP1 (cerliponase alfa) in mouse models of CLN2 disease (2015)

Kohan R, et al, Ceroid lipofuscinosis: the ultrasonic pattern of the disease (2013)

Urayama A, et al, Mannose 6 receptor-mediated cellular uptake of cerliponase alfa (2018)

Gieselmann V, Delivery of therapeutic proteins to the CNS (2018)

Markham A, Cerliponase alfa: first global approval (2017)

Schulz A, et al, Dose-response effect of cerliponase alfa in CLN2 disease (2019)

Weleber RG, et al, Clinical manifestations of the neuronal ceroid lipofuscinoses (2018)

Santorelli FM, et al, Epilepsy in neuronal ceroid lipofuscinoses: clinical features and treatment outcomes (2019)

Mink JW, et al, Motor decline in CLN2 disease: natural history and treatment outcomes (2020)

Adams D, et al, CLN2 disease: clinical rating scale development and validation (2021)

Schulz A, et al, Long-term efficacy of cerliponase alfa in CLN2 disease: 3-year open-label extension data (2020)

Pierpont EI, et al, Cognitive outcomes in CLN2 disease patients treated with cerliponase alfa (2020)

Unknown, CLN2 Disease Registry. Real-world outcomes with cerliponase alfa: 5-year interim analysis. 2023 (2023)

Parenti G, et al, New strategies for the treatment of lysosomal storage diseases (2021)

Biffi A, Gene therapy for metachromatic leukodystrophy (2019)

Giugliani R, et al, Intracerebroventricular enzyme replacement therapy for MPS I: preclinical and clinical considerations (2018)

Byrne BJ, et al, Pompe disease: to treat the heart and the brain (2021)

Unknown, BioMarin Pharmaceutical. Brineura administration guide. 2022 (2022)

Whitley CB, et al, Cerliponase alfa dosing and infusion protocols: consensus recommendations (2019)

Kwon JM, et al, Safety and tolerability of intracerebroventricular enzyme replacement therapy (2020)

Guffon N, et al, Intraventricular access device placement and management in enzyme replacement therapy (2019)

Stepien KM, et al, Pre-infusion assessment and monitoring protocols for cerliponase alfa (2021)

Lund AM, et al, Antihistamine and corticosteroid premedication for cerliponase alfa hypersensitivity (2020)

Thurner A, et al, Optimizing cerliponase alfa infusion parameters (2021)

Harmatz P, et al, Post-infusion monitoring in enzyme replacement therapy: best practice recommendations (2020)

Muenzer J, et al, Neurosurgical aspects of intraventricular access devices for enzyme replacement therapy (2019)

Scarborough P, et al, Device-related infection prevention in cerliponase alfa therapy (2020)

Jones SA, et al, Management of device complications in lysosomal enzyme replacement therapy (2018)

Unknown, FDA. Brineura safety information. Available at: (n.d.)

Wang D, et al, Meningitis in patients receiving intracerebroventricular enzyme therapy: recognition and management (2021)

Specchio N, et al, Seizure management in CLN2 disease: a position paper (2021)

Böhles H, et al, Anaphylactoid reactions to cerliponase alfa: a case series and review (2019)

Wang W, et al, Anti-drug antibody development in cerliponase alfa-treated patients: impact on efficacy and safety (2020)

Rane PB, et al, Peri-procedural antibiotic prophylaxis in enzyme replacement therapy (2020)

Giugliani R, et al, Corticosteroid premedication for immunomodulation in cerliponase alfa therapy (2019)

Hlavata I, et al, Cerebrospinal fluid TPP1 activity as a biomarker of treatment response (2020)

Unknown, FDA News Release. FDA approves first treatment for a rare form of Batten disease. June 1, 2017 (2017)

Unknown, European Medicines Agency. Brineura assessment report. 2017. EMA/CHMP/295269/2017 (2017)

Unknown, Orphan Drug Designations and Approvals. Cerliponase alfa. Available at: (n.d.)

Unknown, Biomarin Patient Assistance Programs. Available at: (n.d.)